Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Technological advances coupled with novel collaborative strategies for compound sourcing and management are poised to transform the utility of high-throughput screening.
Just weeks after an FDA advisory meeting on the use of vaccines in pregnant women to protect newborn babies, Novavax has launched the first ever Phase III trial of a vaccine for maternal immunization licensure.
Approvals of Janssen's daratumumab and Bristol-Myers Squibb's elotuzumab cap a stellar year for multiple myeloma therapies, providing two new mechanisms of action and prompting a slew of combination trials.
With biosimilar monoclonal antibodies now entering the market and a surge of biosimilars expected once the patents for major pioneer products expire, this article analyses experiences so far and future market dynamics.
Dysfunction of voltage-gated calcium channels is associated with a variety of neurological and psychiatric conditions. Several drugs that block these channels are already in clinical use, with new agents currently in development. Here, Zamponi highlights the functions of voltage-gated calcium channels and assesses their potential as therapeutic targets for nervous system disorders.
Inflammatory conditions such as asthma, atopic dermatitis and chronic sinusitis with nasal polyps are caused by type 2 inflammation. In this Review, Gandhiet al. explore the idea that these conditions can be treated by targeting the common proximal drivers of type 2 inflammation, which include interleukin-4 (IL-4), IL-5 and IL-13, and discuss the supporting clinical evidence as well as candidate drugs in development.
As critical regulators of glucose and lipid metabolism, as well as vitamin D and phosphate homeostasis, the endocrine fibroblast growth factors (FGFs) have therapeutic potential in various chronic human diseases. Here, Moschetta and colleagues discuss the physiological roles of FGF19, FGF21 and FGF23, focusing on recent advances and the associated challenges in their therapeutic exploitation.
